News
Efficacy and safety of intramuscular (IM) recombinant Erwinia asparaginase in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): The Children’s Oncology Group (COG) AALL1931 study.
This phase II study demonstrated the efficacy of osimertinib 80 mg daily in patients with EGFR mutant NSCLC with leptomeningeal disease. The study designed included BICR using the RANO-LM assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results